Sumrrmry This study investigates the dynamics of impairment during and after multidrug therapy treatment for the patient cohort of the prospective ALERT MDT Field Evaluation Study (AMFES). The impairment status was compared at intake, at release from treatment (rft), and at the time of the latest survey between 24 and 48 months after release from treatment (follow-up). The eye-hand-foot impairment score (EHF score), which is the sum of the WHO impairment grades of the eyes, hands, and feet, was used as tool for comparison. In all, 433 out of the 592 patients (224 PB and 209 ME) completed treatment in time and were assessed at release from treatment.
Introduction

Dynamics of impairment during and aft er treatment 159
Newly detected leprosy patients may or may not present with impairments. During and after multidrug therapy (MDT), new impairments may develop, and existing impairments may worsen, remain stable or improve. Many studies have addressed the presence of impairments in newly detected patients. I -7 Less attention has been paid to the dynarnics of impairment during and especially after MDT treatment. One study addressed patients in Malawi; 8 other studies were conducted in Asian eountries. 3 , 5 , 9 , lO The percentage of newly detected patients presenting with impairment varied considerably across these studies. Whereas worsening of impairment status was not negligible, the studies revealed that a majority of patients with impairment at release from MDT already had impairment at registration. In only one of these studies, 5 the impairment dynarnics were evaluated during a follow-up period that extended well beyond release from treatment. All studies employed WHO disability grades. The use of the term 'disability' is however questionable. According to the Intemational Classification of Impairments, Dis abilities and Handicaps (ICIDH), 11 disability refers to inability to perform aetivities due to impairment. Impairment is defined as 'any loss or abnormality of psychological, physiological, or anatornical strueture or function'. Under ICIDH, the WHO grades do not reflect disability but impairment. lO Following earlier publications, 7 , 9 , lO this paper will therefore use the term 'WHO impairment grade' instead of 'WHO disability grade'. In the generally known 1988 WHO system, 1 2 grades are assigned to eaeh eye, hand and foot using a scale with three possible outcomes (O, 1, 2). The maximum of these six grades, the 'maximum WHO impairment grade', specifies the patient's overall score. The 1988 WHO system has again been updated in 1998 by re-defining the grades for the eyes Y
The maximum WHO impairment grade recognizes both first onset of impairment and total recovery of existing impairment. Otherwise, its sensitivity to improvement or worsening of impairments is limited. This is of cone em beeause from patient registration onwards, the performance of the serviees of a leprosy control programme is expressed in changes in impairment and disability. Aeeordingly, the 1988 maximum WHO impairment grade has primarily been applied to compare impairment profiles of newly deteeted patients aeross countries. 14 De Rijk et a!. introdueed an altemative summary score, 15 which uses the sum instead of the maximum of the individual grades for eyes, hands and feet. Further study lO of impairment dynarnics promoted the so-ealled Eye-Hand Foot impairment score (EHF score), as demonstrating a higher sensitivity in registering change than the maximum WHO grade. The EHF score has also been suggested as tool for evaluating the effectiveness of steroid programmes. 16 The EHF seore and the maximum WHO impairment grade share the advantage that their components -the individual grades for eyes, hands and feet -are routinely reeorded in leprosy control programmes.
In this paper, the EHF seore is applied to investigate the severity and evolution of impairment over time for the cohort of the ALERT MDT Field Evaluation Study (AMFES). Comparisons are made between EHF scores at intake, at release from treatrnent, and at the latest survey exarnination between 24 and 48 months after release from treatment. Objectives and interim results of the AMFES study, which is conducted within a routine leprosy control programme in central Ethiopia, were deseribed before by de Rij k et a!. 1 5 , 17 160 A. Meima et aI.
Materiais and methods
Methods of enrolment, diagnosis, administration of fixed-duration MDT and case holding in AMFES have previously been specified 1 5 and reviewed l 8 . The present study involves ali enrolled newly detected patients except those who had errors in enrolment procedures or in diagnosis.
Recorded patient characteristics include age, sex, clinicaI classification and bacterio logical index (BI). The type of treatment (PB or MB) was chosen on the basis of clinicaI classification and skin smears. For clinicaI classification, the simplified system for field workers recommended by Jopling l9 was used. It should be recognized that many patients correctly diagnosed as PB in the present study would be classified as MB if presently used criteria focussing on number of skin lesions or number of body areas affected had been applied. 1 3 AMFES patients were scheduled for exarnination at intake, while on MDT, at release from treatment, at 3 and 6 months after release from treatment (rft) and thereafter at intervals of 6 months. Examination involved the recording of the WHO impairrnent grades for the eyes, hands and feet according to the 1988 WHO grade definitions. 1 2 The maximum WHO impairment grade and the sum of these six impairrnent grades for the eyes, hands and feet -EHF score (ranging from O to 12) -follow directly. This paper investigates the dynamics of impairment by comparing the EHF scores at three different points in time: intake, release from treatment, and the time of the latest survey conducted between 24 and 48 months after release from treatment. A considerable number of patients did not complete treatment, and some patients did complete treatment in due time but were not examined at release from treatment. Patients who did complete treatment and who were exarnined at release from treatment are referred to as 'rft patients' . Those among the 'rft patients' who in addition had a survey examination between 24 and 48 months after release from treatment are in this study denoted as 'follow-up' patients. Unless indicated otherwise, the terrn 'worsening' will refer to any increase in EHF score (this includes onset of impairrnent in previously unimpaired patients). 'Improvement' refers to a decrease in EHF score, while 'recovery' indicates that the EHF score has decreased to zero from a previously positive score.
In the data ana1ysis, statistical significance refers to the 5% leveI. Frequency distributions were compared using the Chi-square testo The data analysis was carried out in SPSS.
Results
A total of 603 new patients were enrolled in the AMFES project. Out of these, 11 patients were excluded from the present data ana1ysis because of either incorrect enrolment procedures or incorrect diagnosis. The resulting study cohort consists of 292 PB and 300 MB patients.
THE COHORT OVER TIME
Out of the 592 patients, 454 patients completed treatment in time. The treatment completion rates were higher for PB than for MB patients (PB : 242/292, or 83%, against MB : 212/300, or 71 %, P < 0·001). Thirteen patients died before they could be released from treatment, 104 did not complete treatment and were lost to follow-up, and 21 did not complete treatment in due time but were seen Iater. Twenty-one patients eompleted treatment in time but were not examined by the Ieprosy eontrol supervisor (LCS) at the end of treatment. So, 433 (224 PB and 209 MB) patients eompleted treatment in time and were examined by the LCS at release from treatment.
The 433 rft patients differed from the other 159 patients in the eohort in several respeets. Summarizing, the rft group included more ehildren (PB : 22% against 7%, P < 0·01; MB : 11 % against 5%, P = 0· 1). As eompared to the non-rft group, the MB rft patients more often had high BI values (BI 2:: 3; 75% against 63%, P < 0·05) and Iess often had EHF seores of 3 or more (28% against 41 %, P < 0·05). The pereentage with EHF seore 3 or more was 25 % for both PB rft and non-rft patients.
Out of the 433 rft patients, 323 patients had a follow-up examination between 24 and 48 months after rft (158/224 PB, or 71 %, against 165/209 MB, or 79%; P < 0·05). In eomparing these 'fóllow-up' patients with the 110 rft patients without follow-up (66 PB and 44 MB), again differenees are observed. FemaIes were under-represented in the follow-up group of PB rft patients (37% against 52%, P = 0·05). The age distributions of the PB rft patients with and without follow-up also differed signifieant1y. In the follow-up group, ehildren were over represented (25% against 15%) and young adults (ages 15-29 years) were under-represented (30% against 52%). In MB patients, the pereentages of femaIes were similar (3 1 % against 30%), whereas ehildren and young adults together were over-represented in the follow-up group (58% against 41 %, P = 0·05). The rft patients with follow-up did not differ signifieant1y from the rft patients without follow-up in pereentage with BI 3 or more (MB patients only), pereentage with EHF-seore 3 or more (PB : 27% against 20%, MB : 28% against 25%) and pereentages improving (including reeovery) and worsening in EHF seore between intak:e and rft.
IMPAIRMENT AT INTAKE
TabIe 1 gives details of impairments at intak:e. About haIf of the patients had no impairment. Five pereent of both PB and MB patients had just one extremity or eye affeeted with WHO grade 1 (EHF seore 1). Thirty-three pereent of PB and 39% of MB patients had EHF seores ranging from 2 to 4. The pereentages with EHF seore 5 or more were 11 % for PB and 12% for MB . Between PB and MB, no signifieant differenees were observed in pereentage with any impairment (PB : 50%, MB : 56%) and with WHO grade 2 impairment (PB : 26%, MB : 21 %). PB patients with EHF seores ranging from 2 to 4 more often had at least one extremity or eye affeeted with WHO grade 2 than MB patients (PB : 45 %, MB : 21 %, P = 0·001). AlI patients with EHF seore 5 or more had at least one extremity or eye with grade 2 impairment. Further anaIysis showed that, with two exeeptions for both PB and MB, they all had at least four extremities affeeted (for this analysis both eyes are included with the hands and feet to give a total of six 'extremities'). The large maj ority of the group of alI impaired patients had at least two extremities affeeted (PB : 76%, MB : 87%). 5/224 (2%) PB patients and 3/209 (1-4%) MB patients had eye impairment: alI these patients, exeept for one PB patient, had only grade 1 eye impairment. After re-examining patients with eye problems, data on eyes were eorreeted to refer to eye impairment that is due to leprosy only. Eye impairment figures earlier presented by de Rij k et aI. 15 were therefore higher. Overall, the distribution of EHF se ores did not differ signifieantly between PB and MB patients. at fol/ow-up
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A. Meima et aI. Table 2 . Relation between changes in eye-hand-foot (EHF) score between intake and treatment completion ('intake --+ rft') and between treatment completion and latest assessment between 24 and 48 months after treatment completion ('rft --+ follow-up') for patients who completed treatment and were assessed for impainnent grades at release from treatment and in the post-treatrnent period (percentages of ali patients in brackets). In the Figure 1 summarizes changes in impairment over time for the PB patients. Four of 113 (4%) patients free from impairment at intake had impairment at rft. At the same time, 15/1 11 (14%) initially impaired patients recovered from their impairment. These changes imply that the vast majority of patients with impairment at rft (96 out of 100) already had impairment at intake. Overall, improvement inc1uding recovery was more common than worsening (which inc1udes onset of impairment, 46 versus 18 patients). Nearly half of the initially impaired patients (46%) did not change in EHF score. Between rft and follow-up, the numbers of patients improving or recovering and worsening were very similar with 28 and 27. Having impairment at rft is by far the most important determinant for having impairment at follow-up: 69/74 (93%) of those with impairment at follow-up were already impaired at rft. Table 2 shows the re1ation between changes in EHF score in the two consecutive time intervals. A tendency for compensating changes is most noteworthy. Out of those who improved or recovered during treatment, 33% (12/36) worsened in EHF score after rft, compared to 12% (15/122) for those who stayed the same or worsened during treatment (P < 0·005). Similarly, 62% (8/13) of patients who worsened during treatment improved or recovered after rft, versus only 14% (20/145) of the others (P < 0·001).
EHF score change does not necessarily reftect a patient' s impairment dynamics well because improvement in one extremity or eye may coincide with worsening in another. Between intake and rft, this actually happened in three patients (the EHF score did not change Figure 1 . Changes over time in impainnent status as measured by the eye-hand-foot (EHF) score for PB patients who completed treatrnent and whose impainnent grades were assessed at release from treatment ('PB rft patients '), and for PB rft patients who in addition were assessed for impainnent grades between 24 and 48 months after release from treatrnent ('PB follow-up patients '). in one and improved in two of them). Further analysis revealed the same phenomenon in seven patients after rft. One of them worsened, two did not ehange and four improved in EHF seore. These opposite ehanges imply that 35% (28/79) of the already impaired folIow-up patients worsened in at least one eye or extremity during folIow-up, against 28% (22/79) who worsened in EHF seore.
Further analysis revealed the maxirnum ehange in EHF seore between intake and rft to be three points: one rft patient worsened, and two rft patients improved by three points. The ehange was at least two points in 33% of alI worsening patients, and in 16/39 (4 1%) of improving patients with an initial EHF seore of 2 or more (inc1uding eight reeoveries). Between rft and folIow-up, two patients worsened, and four patients improved by three points or more. The ehange between rft and folIow-up was at least two points in 41 % of all worsening patients, and in 15/25 (60%) of improving patients with an EHF seore of 2 or more at rft (inc1uding seven reeoveries). Overall, no important ehanges oeeurred over time in the distribution of EHF seores for PB patients as a group; the differenees between intake, rft and folIow-up were not statistiealIy signifieant for the rft patients, nor for the folIow-up group (EHF seore eategorization used: O, 1, 2, 3-4, 5-6, 7-12).
DYNAMICS OF IMPAIRMENT IN MB PATIENTS
The EHF seore ehanges for the MB patients are summarized in Figure 2 . In the MB group, reeovery of existing impairment (23 patients) between intake and rft is largely eompensated by first onset of impairment (19 patients). StilI, the vast maj ority of patients with impairment at rft were also already impaired at intake (95/1 14, or 83%, against 96% for PB). Improvement plus reeovery again oeeurred more often than worsening (5 1 versus 34 patients). Over 40% of initi,ally impaired patients (44%) did not ehange in EHF seore.
Between rft and folIow-up, less patients improved than worsened in EHF seore (23 versus 38 patients). In eomparison to earlier ehange, impaired patients less often improved or reeovered (23/88, or 26% against 51/118, or 43%, before rft) and about twiee as often worsened (24/88, or 27%, against 15/118, or 13%). Again, presenee of impairment at rft is by far the most important ueterminant for later impairment: 76/90 (84%, against 93% for PB) patients with impairment at follow-up also had impairment at rft.
A tendeney for eompensating ehanges similar to that for PB patients is observed ( Table  2) . Qut of those who improved or reeovered during treatment, 48% (20/42) worsened in EHF seore after rft, eompared to 15% (18/123) for those who stayed the same or worsened during treatrnent (P < 0,001). Also, 41% (11/27) of patients who worsened during treatment improved or reeovered after rft, versus only 9% (12/138) of the others (P < 0'001).
WHO impairment grades of extremities and eyes also simultaneously ehanged in opposite direetions in MB patients. Qut of the nine patients who experieneed this before rft, three improved in EHF seore and six maintained their seore. Beeause 13% (15/1 18) of the patients with impairment at intake worsened in EHF seore, this implies that 20% (24/1 18) of them worsened in at least one eye, hand or foot. After rft, only two MB patients experieneed Figure 2 . Changes over time in impairment status as measured by the eye-hand-foot (EHF) score for MB patients who completed treatment and whose impairment grades were assessed at release from treatrnent ('MB rft patients'), and for MB rft patients who in addition were assessed for impairment grades between 24 and 48 months after release from treatment ('MB follow-up patients').
simultaneous improvement and worsening (one worsened and two of them did not change in EHF score).
Further analysis also demonstrated notable changes in the MB patients. Between intake and rft, six rft patients worsened, and eight rft patients improved by three EHF points or more. The total change was at least two points in 47% of alI worsening patients, and in 33/47 (70%) of improving patients with an initial EHF score of 2 or more (inc1uding 19 recoveries). Between rft and follow-up, six patients worsened, and one patient improved by 3 points or more. The total change between rft and folIow-up was at least two points in 34% of alI worsening patients, and in 10/20 (50%) of improving patients with an EHF score of 2 or more at rft (inc1uding nine recoveries). Statistically significant differences in the EHF score distributions over time were not observed for the MB patients.
Discussion
The present study confirms the earlier indication that the AMFES cohort is severely affected by impairment and disability. 7 Many patients were impaired at intake, frequently with WHO grade 2 and usualIy with multiple extremities involved. More than 10% of both PB and MB patients had EHF scores of 5 or more. Such scores imply very extensive nerve involvement.
DYNAMICS OF IMPAIRMENT OVER TIME
The dynamics of impairment over time were illustrated by comparing EHF scores between intake and rft, and between rft and follow-up survey. Only a minority of patients with impairment at intake recovered completely. Impairment at the previous assessment was the most important determinant for impairment at the next. The dynamics of impairment were less favourable after rft than before. The risk of becorning impaired was both before and after rft significantly lower for PB than MB patients without previous impairment. During both periods, more than half of the impaired PB and MB patients changed in EHF score. A tendency towards compensation of EHF score improvement before rft by worsening after rft and vice versa was observed. OveralI, the EHF score distributions of the PB and MB groups hardly changed over time.
Although the differences in the EHF score distributions at the different assessments were not statistically significant, the dynamics of impairment after rft deserve special attention. Compared with the treatment period, both PB and MB patients with impairment showed further worsening of their EHF score after rft twice as often. The EHF score measures both primary and secondary impairments. The development of primary impairments (sensory loss and musc1e weakness) relates to active neuritis, which although it occurs, is much less common after rft than before. 2 0 The worsening of the EHF score after rft is therefore likel y to be due to increasing secondary impairment (wounds, ulcers and tissue loss), although the AMFES database does not contain this information in detail. This is in accordance with the suggestion from a study from Thailand that with longer periods after rft, changes in impairment status will more and more be due to new/increased tissue damage (e.g. wounds, bone loss) than to increases in NFI. 5 Drop-out rates in our study were considerable. The greatest number of losses occurred at the time of the overthrowing of the former Ethiopian govemment in 1991. 1 8 Probably, the longer duration of MB treatment contributes to the lower treatment completion rates in MB as compared to PB patients (7 1 % versus 83%). In contrast, follow-up of rft patients was more successful in the MB group (79% examination versus 71 % for PB). The drops-outs before and after rft differed from the other patients in several respects. Significant differences in EHF score change before rft were not observed between patients who did and did not drop out after rft. It must be noted that patients who experience complications may at times both be more prone (need for extra care) and less prone (due to loss of confidence in the programm e, or hiding because of stigma) to complete treatment and to present at follow-up examinations.
Studies that address change in impairment over time 3 , 5 , S -1O are difficult to compare because of differences in case definitions, treatrnent durations and scoring systems for impairment. Still, alI these studies found that clear majorities of patients with impairment at rft already had impairment at registration. One study also addressed change after rft. 5 In contrast to our study, the risks of worsening after rft were lower (but still significant) than before for MB patients and similar for PB patients. The EHF score was only utilized in two studies from Nepa1. 9 , 1 O Both studies addressed the same group of MB patients at diagnosis and exarnination after two years of MDT. The percentage with impairment at diagnosis (44%) was identical to our MB group. Although the percentage of patients with EHF scores of seven or more was higher in the Nepal group (6% versus 2%), the EHF score distributions at diagnosis were overall rather similar. Differences in the EHF score dynarnics between the Nepal study and our study (usually rft was also 2 years later than intake) were observed, but a consistent pattern was not observed.
The dynarnics of the EHF score after rft are worrisome. In addition, little is known about the long-term fate of leprosy patients who have irreversible nerve damage. The years of life lost to disability in this patient group, which accumulates over periods of many years, represents the real burden of leprosy disease. More insight into the size of this group, in the health related problems that they experience, in the care and support that they judge appropriate and in the associated resource requirements is urgently required. This patient group should get the attention in health policy agendas that it is entitled to.
REFLECTlON ON THE USE OF THE EHF SCORE
We chose the EHF score as the evaluation tool for the present study. The EHF score gives a more detailed picture of the impairment status than the maximum WHO grade. In one of the two papers from Nepal, van Brakel et al. l o showed the EHF score to be much more sensitive than the maximum WHO impairment grade : 37% of patients who changed in EHF score did not change in maximum WHO grade. Further analysis showed this difference to be more pronounced in our study.
We agree with van Brakel that the EHF score is not a perfect impairment indicator: it remains a simple sum of the WHO impairment grades of the extremities and eyes. A point of criticism with respect to summary scores such as the EHF score is that they are unable to discriminate between a maj or change in one component and minor changes in several components. But for the WHO grades for extremities and eyes that make up the EHF score, van Brakel et ai. 10 stated that 'a change of one point at any site usually constitutes a major change in impairment status'. In extremities that improved in WHO impairment grade upon corticosteroid treatment, Broekhuis et ai. 1 6 showed the changes in sensory testing (ST) and voluntary muscle testing (VMT) to be important. Nevertheless, the EHF score may mask simultaneous changes of extremities and eyes in opposite directions. The frequency with which this happened in our study group is however not alarrni ng.
The reliability of the EHF score has not yet been established. To our knowledge, the retrospective study by Broekhuis et al. 16 is the only study that investigated the reliability questiono They indicated the hand-foot impairrnent score (sum of the WHO grades for extrernities: HF score) to be a prornising device for the evaluation of the effectiveness of corticosteroid treatment at programme leveI. They aIso demonstrated that the EHF score is not a suitable device for supporting individual patient management. Unfortunately, it is not possible to validate the EHF score on the basis of the AMFES cohort. The main reasons for this are lack of detailed inforrnation on secondary impairrn ent and the fact that the monitoring of AMFES patients was less dose after rft. Compared with other scoring systems, the EHF score has some important advantages. It is simple, reproducible, and inforrnation on its components (the WHO impairrnent grades for extr e rnities) is already routinely collected in many control programmes. 16 Although we acknow ledged a number of deficiencies in the EHF score, we are convinced that they are outweighed by the practical usefulness of the EHF score. Following van Brakel lO and Broekhuis, 16 we therefore strongly recommend initiation of prospective validation studies of the EHF score as tool for the evaluation of activities at programme leveI.
